Milestone Pharmaceuticals Inc.
For the period ended Jun 16, 2025. Filed Jun 16, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jun 16, 2025 · Filed Jun 16, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · About Milestone Pharmaceuticals
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.